Search

Janssen - Fate Therapeutics iPSC CAR NK and CAR-T Collaboration


Sexton Riley LLP Represents Janssen in Worldwide Collaboration Agreement with Fate Therapeutics for Novel iPSC-derived Cell-based Cancer Immunotherapies


April 2020


​Sexton Riley LLP represented Janssen Biotech, Inc., an affiliate of Johnson & Johnson, in its global collaboration and option agreement with Fate Therapeutics, Inc., to research and develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates for the treatment of hematologic malignancies and solid tumors.


Fate Therapeutics' press release is here.


Recent Posts

See All

Julienne Hearn Joins Sexton Riley LLP

Sexton Riley LLP is proud to announce that Julienne Hearn has joined the firm as a partner, as of October 1, 2021. Julienne is a corporate and intellectual property lawyer with extensive experience ad

Janssen - argenx Cusatuzumab Collaboration

Sexton Riley LLP Represents Janssen Affiliate Cilag GmbH International in Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab December 2018 ​Sexton Riley LLP

Janssen - Legend Biotech CAR-T Collaboration

Sexton Riley LLP Represents Janssen in Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy December 2017 ​Sexton Rile